Human chorionic gonadotropin hormone prevents wasting syndrome and death in HIV-1 transgenic mice.
At birth, transgenic mice, homozygous for the HIV-1 provirus pNL4-3, deleted in gag/pol, are normal in appearance and weight. Within several days after birth, the pups develop a syndrome characterized by dry, scaly, hyperkeratotic skin, growth failure, and death. The possibility that the homozygous embryos are being protected during gestation by a maternal factor led us to treat the newborn animals with various pregnancy-related hormones including human chorionic gonadotropin (hCG), estrogen, progesterone, and dexamethasone. Treatment with hCG prevented death, led to normal growth, and markedly reduced skin lesions. In contrast to the skin of the untreated homozygous pups, which expressed high levels of HIV mRNA and proteins (i.e., gp120 and Nef), the skin of the hCG-treated pups showed a marked reduction in both HIV mRNA and proteins. Discontinuation of hCG resulted in the reappearance of HIV transcripts and proteins, skin lesions, and growth failure resulting in death. In addition, HIV transcripts and proteins were reduced significantly in heterozygous mothers during pregnancy, but reappeared after parturition. Similarly, hCG treatment resulted in a decrease of HIV proteins in the skin of nonpregnant heterozygous transgenic mice. These findings suggest that the inhibiting effect of hCG on HIV expression may be clinically useful in the treatment of HIV infections, and may be responsible, during pregnancy, for the low transmission of HIV from infected mothers to their offspring.
De
S K
SK
Laboratory of Oral Medicine, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892, USA. swde@yoda.nidr.nih.gov
Wohlenberg
C R
CR
Marinos
N J
NJ
Doodnauth
D
D
Bryant
J L
JL
Notkins
A L
AL
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000818:Animals; D002100:Cachexia / Q000517:prevention & control*; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D015693:Gene Products, nef / Q000032:analysis; D015699:HIV Envelope Protein gp120 / Q000032:analysis; D015497:HIV-1 / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D011247:Pregnancy; D012333:RNA, Messenger / Q000032:analysis; D054311:nef Gene Products, Human Immunodeficiency Virus
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D015693:Gene Products, nef; D015699:HIV Envelope Protein gp120; D012333:RNA, Messenger; D054311:nef Gene Products, Human Immunodeficiency Virus